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        Introduction 
  In mammalian cells, induction of apoptosis occurs via one of 
two distinct pathways: extrinsic or intrinsic. The extrinsic path-
way responds to extracellular signals through death receptors at 
the plasma membrane (e.g., Fas and TNF-R1), whereas the in-
trinsic pathway is activated by intracellular stress. The intrinsic 
apoptotic cascade involves the release of apoptogenic factors 
(including cytochrome   c   and second mitochondria-derived acti-
vator of caspases [Smac]/Diablo) from mitochondria to the 
cytosol (  Wang, 2001 ;   van Loo et al., 2002 ). The release of apop-
togenic factors requires permeabilization of the mitochondrial 
outer membrane, a process regulated by the Bcl-2 family of pro-
teins, which comprises both proapoptotic (e.g., Bax, Bak, and 
Bid), and antiapoptotic (e.g., Bcl-2 and Bcl-xL) members (  van 
Loo et al., 2002  ). As for extrinsically induced apoptosis, this 
can take the course of either one of two pathways depending on 
cell type. In type I cells, binding of the Fas death receptor in-
duces the   “  death-inducing signaling complex  ”   (DISC) on the 
plasma membrane and activates a large amount of the initiator 
protease, caspase-8, which then cleaves and activates the execu-
tioner protease caspase-3. However, in type II cells, caspase-8 
activation at the plasma membrane is limited, and the apoptotic 
signal relies on amplifi  cation from the mitochondrial apoptotic 
pathway (  Scaffi  di et al., 1998  ). Thus, in type II cells, after the 
activation of Fas at the plasma membrane, the extrinsic apoptotic 
pathway converges with the intrinsic one: caspase-8 cleaves 
Bid to its active form tBid, which induces mitochondrial outer 
membrane permeabilization and release of apoptogenic factors 
(  Li et al., 1998  ;   Luo et al., 1998  ). 
  Cardiolipin (CL), a phospholipid of the mitochondrial 
membrane, participates in several mitochondria-dependent apop-
totic steps (  Gonzalvez and Gottlieb, 2007  ), including the pro-
apoptotic function of Bcl-2 proteins. CL can serve as a  “ docking 
site  ”   for tBid on the mitochondrial membrane (  Lutter et al., 2000  ) 
and is required for Bax activation and mitochondrial outer 
membrane permeabilization (  Kuwana et al., 2002  ). By anchoring 
cytochrome   c   to the mitochondrial inner membrane, CL both fa-
cilitates the electron transport chain and encumbers cytochrome   c  
  C
ardiolipin is a mitochondria-speciﬁ  c phospholipid 
known to be intimately involved with apoptosis. 
However, the lack of appropriate cellular models to 
date restricted analysis of its role in cell death. The matura-
tion of cardiolipin requires the transacylase tafazzin, which 
is mutated in the human disorder Barth syndrome. Using 
Barth syndrome patient-derived cells and HeLa cells in 
which tafazzin was knocked down, we show that cardio-
lipin is required for apoptosis in the type II mitochondria-
dependent response to Fas stimulation. Cardiolipin provides 
an anchor and activating platform for caspase-8 transloca-
tion to, and embedding in, the mitochondrial membrane, 
where it oligomerizes and is further activated, steps that are 
necessary for an efﬁ  cient type II apoptotic response.
  Cardiolipin provides an essential activating platform 
for caspase-8 on mitochondria 
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Barth syndrome lymphoblastoid cells underwent cell death to 
the same extent as measured by propidium iodide (PI) exclusion 
(  Fig. 1 B  ). However, when treated with TNF-     or  with  anti-Fas 
antibody, a dramatic decrease in cell death was observed in the 
CL-defi  cient Barth syndrome  –  derived lymphoblastoid cells 
(  Fig. 1 C  ), which prompted focus on the role of CL in Fas-
mediated apoptosis. FACS demonstrated that cell surface-exposed 
Fas levels were unaltered in CL-defi  cient cells (Fig. S1, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200803129/DC1). 
However, measurement of Annexin V binding to PI-negative cells 
(which is indicative of early apoptotic cells) showed a clear re-
duction in the response of Barth syndrome  –  derived lympho-
blastoid cells to anti-Fas antibody compared with control cells 
(  Fig. 1 D  ). These results indicate that CL-defi  cient lymphoblas-
toid cells are defective in the pathway that links the death recep-
tor with the core apoptotic machinery. 
  Tafazzin knockdown reduces CL levels and 
increases resistance to apoptosis 
  Because CL is a mitochondria-specifi  c phospholipid, it most 
likely plays a role in the mitochondria-dependent response to 
extrinsic apoptotic signals. This step, although dispensable in 
type I cells, is crucial for apoptosis of type II cells. It is of note 
that activated human lymphocytes present a type II response to 
Fas-mediated cell death (  Zhang et al., 1996  ). To elucidate the 
involvement of CL in the type II cascade, HeLa cells were used 
because HeLa cells in which Bid was knocked down with Bid-
specifi  c siRNA showed a decrease in Fas-mediated cell death 
(Fig. S2, A and B, available at http://www.jcb.org/cgi/content/
full/jcb.200803129/DC1) and reduced caspase-3  –  like activity 
(DEVDase), which indicates decreased apoptosome activity 
(Fig. S2 C). Moreover, Bcl-xL overexpression protected these 
cells from Fas-induced apoptosis (Fig. S2 D), further confi  rm-
ing that HeLa cells have a type II response to extrinsic apoptotic 
signals and that a Bcl-2  –  regulated, mitochondria-dependent 
step is required in these cells. 
  To generate a model for Barth syndrome, RNA inter-
ference was used to knock down tafazzin. Short hairpin RNA 
(shRNA)-encoding plasmids were constructed using either a 
  tafazzin -specifi  c sequence or a nonspecifi  c shRNA control. HeLa 
cells were stably transfected, and cell clones (shTaz1, shTaz2, 
shCont1, and shCont2) were isolated. Quantitative PCR analy-
sis showed that in shTaz1 and shTaz2 cells, the endogenous 
  tafazzin   RNA levels were reduced signifi  cantly (Fig. S3, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200803129/DC1). 
A corresponding Western blot for endogenous tafazzin con-
fi  rmed effi  cient knockdown of the protein (  Fig. 2 A  ). Finally, 
the CL pattern of the tafazzin knockdown cells resembled that 
of Barth syndrome  –  derived lymphoblastoid cells (  Fig. 2 B  ). 
  Although the increase in MLCL is modest compared with Barth 
syndrome lymphoblastoid cells, a signifi  cant and comparable 
decrease in CL is evident in shTaz1 and shTaz2 cells with a dra-
matic loss of the major peaks of each cluster of CL species, 
which indicates severely defective maturation of CL (  Fig. 2 B  ). 
Moreover, like Barth syndrome patients (  Vreken et al., 2000  ), 
lack of   tafazzin   in HeLa cells has no effect on other major phos-
pholipids (Fig. S4). 
release during apoptosis, which indicates that the complete re-
lease of cytochrome   c   requires the disruption of its interactions 
with CL (  Shidoji et al., 1999  ;   Ott et al., 2002  ). This is further 
supported by the fact that CL peroxidation, catalyzed by cyto-
chrome   c  , is required for cytochrome   c   release from mitochon-
dria (  Kagan et al., 2005  ). 
  Despite the growing body of evidence implicating CL in 
apoptosis, the mechanism remains unresolved. To address the 
role of CL in apoptosis in a cellular system, Barth syndrome  –
  derived lymphoblastoid cells and Barth syndrome  –  like cells were 
used. Barth syndrome (  Barth et al., 1983  ;   Kelley et al., 1991  ) is 
the only known human genetic disorder where alterations in 
CL metabolism are its primary cause (  Hauff and Hatch, 2006  ; 
  Gonzalvez and Gottlieb, 2007  ). Barth syndrome is caused by 
mutations in   tafazzin   (  Bione et al., 1996  ), which encodes a 
transacylase that directs CL maturation (  Xu et al., 2006  ). After 
synthesis in mitochondria, CL is actively remodeled by tafazzin 
to generate its mature acyl form. CL contains four acyl chains. 
During CL maturation, phospholipase A removes one saturated 
acyl chain to generate monolyso-CL (MLCL) while tafazzin re-
places it with an unsaturated acyl chain taken from phosphati-
dylcholine (PC), a process repeated until remodeling is complete 
(  Xu et al., 2006  ). Therefore, in Barth syndrome, mature CL 
  levels are low, whereas the levels of MLCL are high (  Valianpour 
et al., 2005  ), making it a unique model for studying the role of 
mature CL in apoptosis in intact cells. 
  In this study, we show that CL is required for the type II 
extrinsic apoptotic pathway. In particular, CL is fundamental 
for the formation of an apoptotic signaling platform on the mi-
tochondrial outer membrane supporting the recruitment, oligo-
merization, and processing of caspase-8. This step is critical for 
the release of apoptogenic factors from the mitochondrial inter-
membrane space. We show that unlike the type I response to Fas 
signaling, where caspase-8 is activated on the plasma mem-
brane  ’  s DISC, in the type II response, caspase-8 relocates to 
the mitochondrial outer membrane, where its accumulation and 
activation relies on CL. 
  Results 
  Barth syndrome  –  derived lymphoblastoid 
cells resist induction of the extrinsic 
apoptotic pathway 
  Lymphoblastoid cells derived from Barth syndrome patients 
were used to study the role of CL in apoptosis. These cells were 
isolated from two unrelated patients and were immortalized 
ex vivo using Epstein-Barr virus infection. Both cell lines, termed 
DB105.2 and DB105.3, carry an inactive mutant form of   tafazzin . 
Analysis of the CL levels in the lymphoblastoid cells showed 
low CL and high MLCL in the tafazzin-defi  cient lymphoblas-
toid cell lines when compared with the two control lymphoblas-
toid cell lines DB037 and DB015 (  Fig. 1 A   and not depicted). 
Moreover, the acyl chains of the different CL species in Barth 
syndrome – derived  cells  were  less unsaturated, as determined 
by mass spectrometrical analysis, which showed a shift to higher 
m/z values within each cluster of CLs. In response to intrinsic 
death stimuli, such as etoposide or cisplatin, both control and 683 CARDIOLIPIN IS REQUIRED FOR CASPASE-8 ACTIVITY   • Gonzalvez et al. 
shTaz1 cells were transfected with this mutant to generate a re-
vertant clone (shTaz1R). shTaz1R cells expressed tafazzin to a 
level comparable to the endogenous protein (  Fig. 2 A  ), and CL 
levels were comparable to those of control cells (  Fig. 2 B  ). 
  Importantly, shTaz1R cells were highly sensitive to Fas-induced 
apoptosis (  Fig. 2 C  ). Collectively, these data indicated that ta-
fazzin is required for effi  cient Fas-induced apoptosis. 
 To  confi  rm that loss of mature CL and not the loss of ta-
fazzin itself is the cause of apoptosis resistance in tafazzin-
 defi  cient cells, tafazzin was transiently knocked down for 48 h 
using siRNA oligonucleotides. HeLa cells were transfected with a 
plasmid encoding a GFP-tafazzin fusion protein and with either 
nonspecifi  c or   tafazzin  -targeting siRNAs. The GFP-tafazzin pro-
tein colocalized with the mitochondria-specifi  c fl  uorescent dye 
  Similar to Barth syndrome lymphoblastoid cells, tafazzin 
knockdown HeLa cells were highly resistant to anti-Fas antibody-
induced apoptosis (  Fig. 2 C  ), and after Fas activation, they 
showed reduced DEVDase activity (  Fig. 2 D  ). It is worth 
mentioning that, unlike Barth syndrome lymphoblastoid cells, 
  tafazzin-knockdown HeLa cells were partially resistant to high 
doses of cisplatin or etoposide (unpublished data). This resis-
tance to intrinsic cell death may be caused by the inactive p53 
pathway of HeLa cells, and indicates that in these cells, an alter-
native, CL-dependent apoptotic pathway (potentially via an ex-
trinsic loop) may be needed for effi  cient apoptosis induced by 
chemotherapeutic agents. To confi  rm that the Fas resistance is 
not caused by an off-target effect of the shRNA, silent muta-
tions were introduced into the cDNA of human   tafazzin ,  and 
  Figure 1.       Barth syndrome  –  derived lymphoblastoid cells are resistant to Fas-induced apoptosis.   (A) CL and MLCL proﬁ  le of control (DB037) and 
Barth syndrome  –  derived (DB105.2) lymphoblastoid cells as determined by HPLC-MS. CL-i.s. and PG-i.s. are internal standards of known amounts of 
tetramyristoyl-CL and dimyristoyl-phosphatidylglycerol, respectively. The observed CL clusters (I  –  VI) are: I = 64 carbon atoms (likely 4   ×   16); II = 66 
carbon atoms; III = 68 carbon atoms; IV = 70 carbon atoms; V = 72 carbon atoms (likely 4   ×   18); and VI = 74 carbon atoms. Each peak within a 
given cluster represents the saturation level of the acyl chains ranging from 0 (right) to the maximum 8 (left) double bonds. (B and C) Cell death of 
control (DB037 and DB015) and Barth syndrome  –  derived (DB105.2 and DB105.3) lymphoblastoid cells was analyzed by PI exclusion. Cells were 
treated with either intrinsic (B) or extrinsic (C) apoptotic stimuli for 24 h; 10   μ  M etoposide or 25   μ  M cisplatin were used as intrinsic stimuli, whereas 
anti-Fas antibody (0.5   μ  g/ml) or recombinant TNF-     (20 ng/ml) together with cycloheximide (CHX; 20   μ  g/ml) were used as extrinsic stimuli. (D) Cells 
were treated with anti-Fas antibody, and the kinetics of apoptosis was measured by FITC-annexin V staining of PI-negative cells. Error bars represent 
  ±   standard deviation.     JCB • VOLUME 183 • NUMBER 4 • 2008  684
  Cytochrome   c   release is impaired in 
Fas-induced CL-deﬁ  cient cells 
 To understand the role of CL in Fas-induced apoptosis, the known 
steps of this pathway were investigated in tafazzin-knockdown 
cells. Caspase-3, which in type II cells requires cytochrome   c  
release and apoptosome formation for its activation, showed a 
marked decrease in both autocleavage and cleavage of its sub-
strate poly-ADP ribose polymerase (PARP;   Fig. 3 A  ). Next, the 
Fas-induced release of cytochrome   c   and Smac/Diablo from 
mitochondria of tafazzin-knockdown cells was analyzed by 
  immunostaining. It is worth mentioning that the levels of cyto-
chrome   c   within the mitochondria were unaltered in untreated 
cells regardless of the CL status (  Figs. 3 B and 4 C  ). Although in 
many control cells (  Fig. 3 B and C  , white arrows), cytochrome   c   
tetramethyl rhodamine ethyl ester (TMRE), confi  rming its loca-
tion in the mitochondria, and was effi  ciently knocked down in 
cells transfected with   tafazzin -specifi  c siRNA (Fig. S5 A, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200803129/DC1). 
The effi  ciency of the tafazzin-targeting siRNA was further veri-
fi  ed by Western blot analysis (Fig. S5 B). However, under these 
conditions, the CL pattern was unaltered in these cells, likely 
because of the low turnover of the lipids in these cells (Fig. S5 C). 
It was previously shown that, in the liver, the half-life of CL is 
the longest of all mitochondrial phospholipids (  Landriscina 
et al., 1976  ). Importantly, transient depletion of tafazzin (without 
affecting the CL level) in HeLa cells did not modify the sensitiv-
ity of these cells to Fas-induced apoptosis (Fig. S5 D), ruling out 
a CL-independent role for tafazzin in the apoptotic process. 
  Figure 2.       Tafazzin-deﬁ  cient HeLa cells display low CL levels and are resistant to Fas-induced apoptosis.   (A) Cells were stably transfected with either control 
shRNA-encoding plasmid (shCont1 and 2) or with   tafazzin  -targeting shRNA (shTaz1 and 2). Western blot analysis of endogenous tafazzin protein was 
used to conﬁ  rm efﬁ  cient knockdown of the protein. The shTaz1R clone was generated by reintroducing shRNA-resistant cDNA of tafazzin into shTaz1 cells. 
(B) The CL and MLCL proﬁ  le of shCont1, shTaz1, shTaz2, and shTaz1R cells was analyzed as in   Fig. 1 A  . (C) Cell death analysis of the control, tafazzin-
deﬁ  cient, and revertant clone (shTaz1R) was performed 48 h after treatment with anti-Fas antibody. (D) DEVDase (caspase-3  –  like) activity of the indicated 
cells was performed 8 h after anti-Fas antibody treatment. Error bars represent   ±   standard deviation.     685 CARDIOLIPIN IS REQUIRED FOR CASPASE-8 ACTIVITY   • Gonzalvez et al. 
  tBid induces mitochondrial outer membrane 
permeabilization and apoptosis of 
CL-deﬁ  cient cells 
  It was previously suggested that in the mitochondria-dependent 
step of apoptosis, CL enables tBid docking and supports Bax 
oligomerization on the mitochondrial outer membrane (  Lutter 
et al., 2000  ;   Kuwana et al., 2002  ). However, transient transfec-
tion with a tBid-expressing vector showed tafazzin-knockdown 
and Smac/Diablo appeared in the cytosol after Fas activation, 
both proteins were retained in the mitochondria in all CL-
defi  cient cells (  Fig. 3, B and C  ). Western blot analysis of cyto-
solic fractions confi  rmed a block in cytochrome   c   release from 
the mitochondria of tafazzin-knockdown cells after Fas activa-
tion (  Fig. 3 D  ). Therefore, the apoptotic block in CL-defi  cient 
cells is caused by defects in mitochondrial outer membrane per-
meabilization or upstream events. 
  Figure 3.       Tafazzin-deﬁ  cient cells are defective in cytochrome   c   and Smac/Diablo release from mitochondria and in the activation of caspase-3 after Fas activation. 
  (A) Caspase-3 activity of control (shCont1) and tafazzin-deﬁ  cient HeLa cells (shTaz2) was monitored in untreated, anti-Fas antibody-treated for 14 h (Fas), and 
anti-Fas antibody  –   and DEVD-fmk  –  treated cells (FasDEVD). PARP and caspase-3 cleavage, both known caspase-3 targets, were analyzed by Western blotting. 
(B) Cytochrome   c   release from mitochondria before and after a 14-h treatment with anti-Fas antibody in the presence of DEVD-fmk was analyzed in control (shCont1) 
and tafazzin-knockdown (shTaz2) cells by immunostaining. The release of cytochrome   c   was evident in several cells in each microscopic ﬁ  eld, judged by the dif-
fusion of the protein in the cytosol and by the overall lower intensity of the immunostained protein (white arrows). Cells in which cytochrome   c   is retained in the 
mitochondria (punctuated staining and high intensity) are indicated by green arrows. DAPI was used to stain the nuclei. (C) Smac/Diablo release was analyzed 
as for cytochrome   c  . (D) Cytochrome   c   release was detected by a Western blot analysis of cytosolic fractions of the indicated cells treated as in B. Bars, 10   μ  m.     JCB • VOLUME 183 • NUMBER 4 • 2008  686
  Figure 4.       CL-deprived mitochondria efﬁ  ciently 
release cytochrome   c   and Smac/Diablo after 
treatment with recombinant tBid protein.  
(A) The indicated cells were transfected with 
either empty vector control (EGFPN1) or with 
a plasmid encoding either full-length Bid pro-
tein fused to GFP (BidGFP) or a fused tBid-GFP 
protein (tBidGFP). Cell death was assessed 
by PI exclusion in GFP-positive cells by FACS 
analysis. Error bars represent   ±   standard de-
viation. (B) A cytochrome   c  –    releasing assay of 
mitochondria isolated from control (DB037) or 
Barth syndrome  –  derived lymphoblastoid cells 
(DB105.2 and DB105.3). Mitochondria were 
either left untreated (u) or treated with increas-
ing amounts of tBid (0.05, 0.1, 0.2, 0.5, 1, 5, 
10, and 50 nM). Triton X-100 was used as a 
positive control for maximal cytochrome   c   re-
lease. In all cases, cytochrome   c   was efﬁ  ciently 
released to the supernatant buffer when mito-
chondria were treated with tBid concentrations 
of 0.5 nM or higher. (C) Mitochondria were 
isolated from control-transfected (shCont1) or 
tafazzin knockdown (shTaz2) HeLa cells, and 
were either left untreated (u) or treated with 
increasing amounts of tBid (0.05, 0.1, 0.25, 
0.5, and 5 nM). Cytochrome   c   and Smac/
Diablo were analyzed in the supernatant (Sup) 
and cytochrome   c  , and tBid (translocated 
to the mitochondria) and subunit 6 of com-
plex I (as mitochondrial loading control) were 
analyzed in the mitochondrial pellet (Mito). 
Efﬁ  cient release of cytochrome   c   and Smac/
Diablo from the mitochondria as well as the 
translocation of tBid to the mitochondria 
were  identiﬁ   ed at tBid concentrations equal 
to 0.1 nM or higher. (D and E) Mitochondria 
were isolated from control or tafazzin-deﬁ  cient 
lymphoblastoid cells (D) or HeLa cells (E), and 
Bak oligomerization on the mitochondria was 
analyzed after treatment without (u) or with 
increasing amounts of tBid, as indicated in 
B and C. BMH (protein cross-linker) or DMSO 
(control solvent) were added after incubation 
with tBid. No higher molecular weight forms 
of Bak were observed in the absence of BMH, 
even when the maximal tBid concentration 
was added (E, right). Asterisks indicate multim-
ers of the Bak protein.     687 CARDIOLIPIN IS REQUIRED FOR CASPASE-8 ACTIVITY   • Gonzalvez et al. 
cells to be as sensitive as control cells to tBid-induced cell death 
(  Fig. 4 A  ). Isolated mitochondria from either control, Barth 
  syndrome  –  derived lymphoblastoid, shCont1 HeLa, or shTaz2 
HeLa cells were then incubated with increasing amounts of re-
combinant tBid protein, and the release of cytochrome   c   and 
Smac/Diablo was analyzed. In agreement with the results ob-
served in cells, the response of CL-defi  cient mitochondria to 
tBid was comparable to control mitochondria (  Fig. 4, B and C  ). 
Moreover, tBid incorporated into mitochondria (  Fig. 4 C  ) and 
induced Bak oligomerization (  Fig. 4, D and E  ) to the same ex-
tent in both tafazzin-defi  cient and control cells. The explanation 
for these surprising observations could be that the less-mature 
CL in tafazzin-defi  cient cells is suffi  cient for tBid interaction 
with mitochondria. Indeed, it has been previously demonstrated 
that tBid can effi  ciently interact with MLCL (  Esposti et al., 2003  ; 
  Liu et al., 2005  ). However, these observations clearly indicate 
that the block to apoptosis in tafazzin-defi  cient cells lies up-
stream to tBid activity. 
  Activation of caspase-8 on the 
mitochondria requires CL 
  Bid cleavage was then analyzed in control and tafazzin-defi  cient 
cells. Because of technical diffi  culties in immunodetecting tBid 
in total cell extracts, changes in the levels of full-length Bid rather 
than of tBid were initially measured. Fas activation decreased the 
levels of full-length Bid in control but not in CL-defi  cient cells, 
which indicates a block in Bid processing (  Fig. 5, A and B  ). 
To detect tBid directly, mitochondria from control and tafazzin-
knockdown HeLa cells were isolated before and after Fas activa-
tion. As expected, tBid was clearly detected on mitochondria of 
Fas-activated control cells, whereas on mitochondria of tafazzin-
knockdown cells, tBid formation was markedly reduced (  Fig. 5 C  ). 
Because Bid is cleaved by caspase-8 after Fas activation, it 
seemed likely that in tafazzin-defi  cient cells, Bid was not pro-
cessed because of the inactivity of caspase-8. Therefore IETDase 
(caspase-8  –  like) activity was monitored in lymphoblastoid and 
HeLa cells, and was indeed found to be diminished in tafazzin-
defi  cient cells (  Fig. 5, D and E  ). 
  Caspase-8, which is an initiator caspase, is activated by 
induced homoproximity that leads to autoprocessing of the 
proenzyme to a mature, more potent form (  Chen et al., 2002  ; 
  Donepudi et al., 2003  ). Upon homodimerization, procaspase-8 
(p55) is fi  rst cleaved between its two active subunits, p10 and 
p18, to generate the p43/p10 heterodimer (  Fig. 6 A  ). Then, cleav-
age of p43 between the death effector domain (DED) and the 
p18 subunit produces the fully active p18  –  p10 form. To follow 
caspase-8 processing in the different cell lines, immunospecifi  c 
antibodies against the autocleavage products of caspase-8 were 
used. As can be seen in   Fig. 6 (B and C)  , caspase-8 autocleav-
age products are notably low in both Barth syndrome  –  derived 
lymphoblastoid cells (  Fig. 6 B  , compare lanes 2 and 5) and ta-
fazzin knockdown HeLa cells (  Fig. 6 C  , compare lanes 2 and 3 
with 6 and 7). To specifically analyze caspase-8 activation, 
biotinylated-VAD-fmk peptide (bVAD) was used. bVAD binds 
and inhibits active caspases, and hence is used to precipitate the 
fi  rst initiator caspase activated in cells after an apoptotic insult 
(  Tu et al., 2006  ). bVAD precipitated high amounts of active 
caspase-8 (p43) from Fas-activated control HeLa cells (  Fig. 6 D  ). 
However, a signifi  cant reduction in precipitated active caspase-8 
was observed in tafazzin-defi  cient HeLa cells (  Fig. 6 D  ). Together, 
  Figure 5.       Caspase-8 activity is abrogated in 
tafazzin-deﬁ  cient cells.   (A) Control lympho-
blastoid cells (DB037, lanes 1 and 3; DB015, 
lanes 2 and 4) and Barth syndrome  –  derived 
lymphoblastoid cells (DB105.2, lanes 5 and 7; 
DB105.3, lanes 6 and 8) were either untreated 
or treated with anti-Fas antibody (Fas) for 14 h. 
Total cells extract was analyzed by Western 
blotting for Bid levels. After digital scanning of 
the immunoblot, the intensities of Bid levels as a 
percentage of actin levels were plotted (bottom). 
(B) Control (shCont1) and tafazzin-knockdown 
(shTaz1) HeLa cells were either untreated or 
treated with anti-Fas antibody for 14 h, and 
analyzed as in A. (C) Mitochondria were iso-
lated from the indicated cells treated as in B, 
and the tBid levels on the mitochondria were 
analyzed by Western blotting. Subunit 6 of 
complex I was used as a mitochondrial marker 
and loading control. After digital scanning of 
the immunoblot, the intensities of tBid levels as 
a percentage of complex I levels were plotted 
(bottom). (D and E) The indicated control or 
tafazzin-deﬁ  cient cells were treated as in A and 
analyzed for IETDase (caspase-8  –  like) activity. 
Error bars represent   ±   standard deviation.     JCB • VOLUME 183 • NUMBER 4 • 2008  688
end, control lymphoblastoid cells were treated with anti-Fas anti-
body in the presence of the effector-caspase inhibitor DEVD-
fmk. No change in the early processing of procaspase-8 to its 
product p43 was observed (  Fig. 6 B  , top, compare lanes 2 and 3). 
However, DEVD-fmk signifi  cantly blocked the processing of 
p43 into its fully mature p18  –  p10 form (  Fig. 6 B  , middle, compare 
lanes 2 and 3). Similar results were obtained in control HeLa 
these results strongly indicate defective caspase-8 activation in 
CL-defi  cient cells. 
  Even though caspase-8 is an important initiator caspase in 
the Fas signaling response, it was necessary to test whether the 
decrease in caspase-8 activity in tafazzin-defi  cient cells results 
from a decrease in the amplifi  cation loop signaling from cas-
pase-3 or caspase-6 back to caspase-8 (  Slee et al., 1999  ). To this 
  Figure 6.       Caspase-8 processing is defective 
in tafazzin-deﬁ  cient  cells.   (A) A schematic 
diagram of caspase-8 autoprocessing during 
Fas-mediated apoptosis. (B) Control and Barth 
syndrome  –  derived lymphoblastoid cells were 
treated as in   Fig. 5 A   and analyzed by Western 
blotting for caspase-8 cleavage. Two different 
antibodies were used: anti-DED of caspase-8 
and anti-p18 domain (which also detects the 
cleaved p43 form). (C) Control and tafazzin-
knockdown HeLa cells were treated as in 
  Fig. 5 B   and analyzed for caspase-8 cleav-
age as in B. (D) The different HeLa-derived 
clones were treated with anti-Fas antibody as 
indicated for 14 h. The lysates were incubated 
with biotin  –  VAD-fmk to precipitate active cas-
pases, and active caspase-8 was detected by 
immunoblotting. The graph represents a densi-
tometric analysis of the p43 immunoblot as a 
percentage of total actin levels. (E) MCF-7 cells 
were either left untreated or treated with either 
TNF-     together with cycloheximide (TNF-    ) or 
anti-Fas antibody (Fas). Caspase-8 process-
ing was assessed by the anti-p18 antibody. 
(F) shCont1 and Bcl-xL  –  expressing HeLa cells 
were treated as in   Fig. 5 B  , and caspase-8 
activation was assessed by anti-DED (top) or 
anti-p18 (middle) antibodies.     689 CARDIOLIPIN IS REQUIRED FOR CASPASE-8 ACTIVITY   • Gonzalvez et al. 
suggested that caspase-8 is only partially inserted into the mito-
chondrial outer membrane, where it mostly faces the cytosol. 
  The question remained as to how caspase-8 interacts with 
CL on the mitochondria. CL accumulates at the contact sites 
between the inner and outer mitochondrial membranes, where it 
facilitates tBid translocation to the mitochondria (  Ardail et al., 
1990 ;  Hovius et al., 1990 ;  Simbeni et al., 1991 ;  Lutter et al., 2001 ; 
  Kim et al., 2004  ). One possibility was that the enzyme translo-
cates to the mitochondria together with its known substrate, Bid. 
However, in Bid knockdown cells, caspase-8 translocation to 
the mitochondria after Fas activation was unaffected (  Fig. 7 F  ). 
Caspase-8 interaction with the mitochondria may be mediated 
by other proteins ( Stegh et al., 2002 ). However, as was described 
for tBid, it is plausible that in addition to formation of protein  –
  protein interactions, caspase-8 also interacts directly with the CL, 
where CL facilitates and strengthens the protein  –  membrane as-
sociation. To test this possibility, liposomes containing the lipid 
composition of the mitochondrial contact sites were incubated 
with in vitro  –  translated caspase-8. Liposomes in which CL 
was replaced with PC and phosphatidylethanolamine (PE) were 
used to investigate the exclusive requirement for CL in caspase-8 
binding. Analysis of the precipitated liposomes showed no sig-
nifi  cant changes in p55 pro  –  caspase-8 interaction with CL-
  containing as compared with CL-defi  cient liposomes (  Fig. 7 G  ). 
These results are in line with the results observed in isolated 
mitochondria (  Fig. 7 B  ). However, as with mitochondria, the levels 
of p43 autoprocessed form were signifi  cantly reduced in CL-
defi  cient as compared with CL-containing liposomes (  Fig. 7 G  ). 
Importantly, there is a signifi  cant enrichment of the p43-processed 
form of caspase-8 in CL-containing liposomes as compared 
with the input (in vitro  –  translated p55). This may be either due 
to the activation by proximity of pro  –  caspase-8 on the liposome 
or because of the fact that once cleaved in the buffer, p43 has 
an increased affi  nity to the membrane. The stability of the inter-
action between in vitro translated caspase-8 and CL-containing 
liposomes was assessed after washing the precipitated lipo-
somes in 0.1 M Na  2 CO 3  , pH 11.5, or in 1 M NaCl. A small frac-
tion of caspase-8 was extractable, but the majority remained 
associated with the liposomes (  Fig. 7 H  ). Altogether, these re-
sults suggested a stable insertion of caspase-8 into the lipo-
somes, which are mediated by hydrophobic interactions with CL. 
This however, does not rule out the possibilities that electro-
static interactions with CL and/or protein  –  protein interactions 
also facilitate caspase-8 interaction with the mitochondria. 
  Importantly, after Fas activation in both tafazzin-knockdown 
and control cells, the cytosolic procaspase-8 was fully cleaved 
into its early mature form (p43;   Fig. 7 B  , lanes 2 and 4). This 
  indicates that in the cytosol, the initiating process of caspase-8 
cleavage (on the DISC) is unaffected in tafazzin-knockdown 
cells, and that the major defects in these cells lie in the steps 
of docking and activation of caspase-8 on the mitochondria. 
In type II cells, the activation of caspase-8 on the DISC is limited, 
hence the need for a mitochondria-mediated amplifi  cation step. 
To test whether loss of CL hinders only the mitochondria-
dependent (but not mitochondria-independent) apoptotic steps, a 
caspase-8  –  GFP fusion protein was transiently expressed in HeLa 
cells. This fusion protein can oligomerize and self-activate in 
cells (  Fig. 6 C  ; compare lanes 2 and 3 with lane 4). Interest-
ingly, a block in p18 but not in p43 formation was also observed 
in Fas-activated cells treated with the pan-caspase inhibitor 
zVAD-fmk (unpublished data). These results indicate that a 
 caspase-dependent  amplifi  cation loop is not required for early 
processing of caspase-8 to p43 and also show that the fi  rst cleaving 
step of caspase-8, induced by its dimerization, is not inhibited 
by zVAD-fmk. To bypass the use of pharmacological inhibition 
of caspases, MCF7 cells, which carry an inactive mutant form 
of caspase-3, were analyzed. MCF7 cells do not express Fas and 
therefore did not respond to anti-Fas antibody, but when treated 
with TNF-    , even though they were protected from cell death, 
formation of p43 but not of p18 was clearly observed (  Fig. 6 E  ). 
In addition, similar results were obtained in HeLa cells in which 
mitochondria-dependent apoptosis upstream of caspase-3 activity 
was blocked by overexpression of Bcl-xL (  Fig. 6 F  ). Put to-
gether, these results indicate that although caspase-3 amplifi  cation 
(downstream to the mitochondria) is required for full activation 
of caspase-8, it is not required for the early stage of caspase-8 
processing. Because in CL-defi  cient cells the block in caspase-8 
activation is seen in the initial processing of procaspase-8 into 
p43 (  Fig. 6, B and C  ), the CL-dependent apoptotic step is most 
likely independent of caspase-3 and lies either at or upstream of 
the mitochondrial steps of apoptosis. 
  It was previously found that caspase-8 interacts with mi-
tochondria under both physiological (  Stegh et al., 2000  ) and 
apoptotic conditions (  Stegh et al., 2002  ;   Chandra et al., 2004  ). 
Seeing that a mitochondrial lipid affected caspase-8 activity 
in type II apoptotic signaling, we investigated whether CL is 
required for caspase-8 interaction and activation on the mito-
chondria. Cytosolic and mitochondrial fractions of control, 
tafazzin-defi  cient lymphoblastoid and HeLa cells were isolated 
before and after Fas activation and analyzed for caspase-8 lev-
els. Although after Fas-activation, mitochondria of control cells 
displayed cleaved caspase-8 products, including p43 and p18 
(  Fig. 7, A and B  , lane 6), on mitochondria of CL-defi  cient cells, 
these products were signifi  cantly reduced (  Fig. 7, A and B  , 
compare lanes 6 and 8). The activity of caspase-8 on isolated 
mitochondria was measured using benzyloxycarbonyl-Leu-Glu-
Thr-Asp (zLETD)-aminoluciferin as a substrate. LETDase activ-
ity was much higher in mitochondria isolated from Fas-activated 
control HeLa cells compared with the tafazzin-defi  cient HeLa 
cells (  Fig. 7 C  ), which indicates a defect in caspase-8 process-
ing in tafazzin-defi  cient mitochondria. This suggests that mito-
chondria are a required location for full activity of caspase-8. 
Importantly, the p43 and p18 mitochondria-associated products, 
and to a lesser extent procaspase-8 or the DED domain, were 
resistant to alkaline wash (  Fig. 7 D  ). This indicates the strong 
insertion of the p18-exposed isoforms of caspase-8 into the mi-
tochondrial membrane. To determine if caspase-8 completely 
inserts into the mitochondria, mitochondria were isolated from 
HeLa cells that had been transiently transfected with the par-
tially active caspase-8 mutant C360S fused to GFP in the pres-
ence of zVAD-fmk (for more details on this mutant, see   Fig. 8 C  ). 
The isolated mitochondria were incubated with increasing con-
centrations of trypsin. The data indicated that C360S-GFP and 
p43-C360S were sensitive to trypsin treatment (  Fig. 7 E  ) and JCB • VOLUME 183 • NUMBER 4 • 2008  690
  Figure 7.       Caspase-8 translocation to the mitochondria is blocked in CL-deﬁ  cient cells.   (A) Control (DB015) and Barth syndrome  –  derived (DB105.2) 
lymphoblastoid cells were either left untreated or treated with anti-Fas antibody for 24 h. Cytosolic and mitochondria-enriched fractions were isolated, 
and caspase-8 localization and autoprocessing was analyzed by Western blotting using the anti-DED antibody. Subunit 6 of complex I was used as a 
mitochondrial marker and loading control. (B) The different HeLa-derived clones were treated as indicated, and cells were fractionated to cytosolic and 
mitochondria-enriched fractions. The cleaved products of caspase-8 were analyzed with the anti-p18 antibody. Subunit 4 of complex IV was used as a 
mitochondrial marker and loading control. (C) Mitochondria were isolated from HeLa cells treated with anti-Fas antibody as indicated. The cleavage of 
zLETD-aminoluciferin was used to assess caspase-8 activity on the mitochondria. The graph shows the relative levels of emitted signal from the experiment 
displayed in arbitrary units of luminescence (RLU) per microgram of protein. Error bars represent   ±   standard deviation. (D) Mitochondria were isolated from 
HeLa cells treated with anti-Fas antibody and either washed with MIB only or with alkaline MIB. The pellet and supernatant of each wash were analyzed 
for caspase-8 (DED and p18 domains). The different cleaved products of caspase-8 are indicated on the right. Succinate dehydrogenase complex subunit B 
(SDHB) was used as a control for loosely attached proteins, and complex I and Bak were used as control for membrane-inserted proteins. (E) Mitochondria 
were isolated from HeLa cells transfected with caspase-8  –  C360S  –  GFP in the presence of zVAD-fmk. Isolated mitochondria were subjected to trypsin diges-
tion at the indicated concentrations. Mitochondrial pellets were analyzed by immunoblotting. (F) HeLa cells were transiently transfected with either control 
siRNA (scRNA) or siRNA targeting Bid (siBid), as in Fig. S2 (available at http://www.jcb.org/cgi/content/full/jcb.200803129/DC1). 48 h later, cells 
were either left untreated or treated with anti-Fas antibody for 14 h. Mitochondria were then isolated, and caspase-8 localization and autoprocessing was 691 CARDIOLIPIN IS REQUIRED FOR CASPASE-8 ACTIVITY   • Gonzalvez et al. 
  Finally, it was investigated whether caspase-8 transloca-
tion to the mitochondria is required for its activation. As mentioned 
before, initiator caspases are activated via induced proximity, 
and it seemed possible that after its insertion into the CL-enriched 
mitochondrial membrane, caspase-8 dimerizes and autopro-
cesses to become activated. Therefore, caspase-8 oligomeriza-
tion on the mitochondrial membrane after Fas activation was 
examined. Isolated mitochondria from Fas-activated shCont1 
cells were treated with the cross-linker   Bis -maleimidohexane 
(BMH). p43 monomers were noted in control (DMSO) lanes 
but were absent in the BMH-treated lanes. However, higher mo-
lecular weight oligomers were present in the BMH-treated mi-
tochondria lanes (  Fig. 9  ). In particular,     53-kD and    80-kD 
forms were observed, which indicates that upon mitochondrial 
translocation, caspase-8 forms a p43/p10 homo-heterodimer 
(  Fig. 9  ). This tetrameric form of caspase-8 is known to be active 
(though not to its full capacity) and can explain the caspase-8 
activity observed on isolated mitochondria (  Fig. 7 C  ). However, 
this form may be an intermediate on its way to be processed to 
form the p18  –  p10 fully active complex. The fate of this caspase-8 
form is still unclear and is under investigation. Interestingly, how-
ever, higher molecular weight forms were also observed, indicat-
ing that caspase-8 may further oligomerize on the mitochondria 
or that it is associated with other mitochondrial proteins. It is of 
note that once cleaved from p43, the DED domain (p26) on its 
own is no longer affected by the cross-linker and is probably re-
leased from the oligomer when caspase-8 is further processed to 
its fully active p18  –  p10 form. To summarize: the localization, 
oligomerization, and cleavage of caspase-8 on the mitochondria 
after Fas activation, and the defi  cits in these processes in CL-
defi  cient cells, strongly indicates that CL provides an activating 
platform for caspase-8 on the mitochondria after Fas stimulation. 
  Discussion 
  Several studies have previously shown that CL is involved in 
the mitochondria-dependent steps of apoptosis (  Lutter et al., 
2000  ;   Kuwana et al., 2002  ;   Liu et al., 2004  ;   Kim et al., 2004  ; 
  Gonzalvez et al., 2005a  ,  b  ;   Kagan et al., 2005  ). However, until 
recently, the role of CL in apoptosis was not addressed directly 
in cells. After the identifi  cation of human CL synthase, the role 
of CL in apoptosis was studied in a mammalian cell model in 
which CL synthase was knocked down. However, these cells 
displayed severe bioenergetic defects that led to accelerated cell 
death with necrotic features (  Choi et al., 2007  ). In this work, the 
role of CL was investigated using novel cell models of Barth 
syndrome patient-derived cells and tafazzin knockdown HeLa 
cells, which contain signifi  cantly reduced amounts of mature CL. 
These CL-deprived cells are resistant to Fas-induced apoptosis. 
However, their mitochondria are fully capable of undergoing 
the cytosol in the absence of Fas signaling, inducing a type I  –
  like response (unpublished data). When overexpressed in HeLa 
cells, caspase-8  –  GFP induced cell death, which could not be 
blocked by Bcl-xL (  Fig. 8, A and B  ). Because the tafazzin-
knockdown cells are GFP positive (see Materials and methods 
for details), cell death after caspase-8  –  GFP transfection was as-
sessed in these cells by PARP cleavage, an indicator for caspase-3 
activation. As can be seen in   Fig. 8 B  , overexpressing caspase-8  –
  GFP induced comparable cell death in both control and tafazzin 
knockdown cells. These results indicate that like Bcl-xL over-
expression, tafazzin knockdown provides protection from the 
mitochondria-dependent but not from the mitochondria-independent 
apoptotic steps. 
  The point mutation C360S within the catalytic domain of 
caspase-8 reduces its activity but preserves its autoprocessing into 
p43 (  Chang et al., 2003  ). When transfected into HeLa cells, the 
C360S-GFP was partially processed into p43 but not into p18 
(  Fig. 8 C  ). As discussed earlier, this autoprocessing can occur 
even in the presence of zVAD-fmk, which in the following experi-
ment was used to prevent cell death and further processing of the 
mutated enzyme by other caspases (as part of the amplifi  cation 
loop). To investigate whether the exogenous caspase-8 fusion pro-
tein translocates into the mitochondria in a CL-dependent manner, 
shContl and shTaz2 were transiently transfected with C360S  –  m-
Cherry (a fusion protein of monomeric red fl  uorescent protein and 
the C360S point mutant). This was done to avoid using green fl  uo-
rescence in these GFP-positive cells. Under these conditions, 
when shCont1 cells were transfected with C360S  –  m-Cherry, the 
vast majority of transfected cells (  >  70%) showed mitochondrial 
localization of the fusion protein (  Fig. 8 D  , top). Mitochondria 
were visualized in this experiment by immunostaining for TOM20. 
It is important to indicate that even after autoprocessing, the 
C-terminally tagged m-Cherry, which is fused to the cleaved p10, 
would colocalize with p43 on the mitochondria as a heterodimer. 
In contrast, when the C360S  –  m-Cherry mutant was expressed in 
tafazzin knockdown cells, the majority of cells showed a diffused 
cytosolic pattern (  Fig. 8 D  , bottom). The BH3-only protein tBid 
has been shown to interact exclusively with liposomes that contain 
CL (  Lutter et al., 2000  ), and electron tomogram studies showed 
that tBid interacts with the contact sites of mitochondrial mem-
branes, an area rich in CL (  Lutter et al., 2001  ). Colocalization be-
tween tBid and caspase-8 would therefore suggest that caspase-8 
also localizes to CL-enriched domains of the mitochondria. Con-
trol HeLa cells were cotransfected with tBid-GFP and C360S  –  m-
Cherry in the presence of zVAD-fmk and imaged by confocal 
microscopy. Colocalization was observed between tBid and cas-
pase-8 (  Fig. 8 E  ). These results provide further support for the ob-
servation that caspase-8 interaction with the mitochondria is CL 
dependent, and suggest that, like tBid, caspase-8 also localizes to 
CL-rich domains on the mitochondrial contact sites. 
detected by Western blotting using the anti-DED antibodies. Subunit 6 of complex I was used as loading control. (G) Liposomes were prepared with or 
without CL and incubated for 30 min at 37  °  C with in vitro translated procaspase-8 protein. Liposomes were then precipitated and washed, and caspase-8 
binding to the lipid membrane was analyzed by Western blotting. The input lane represents 20% of the sample after incubation with caspase-8 but before 
precipitation. The graph shows the relative intensity of the different caspase-8 forms on liposomes with or without CL, and is the mean and standard devia-
tion of three independent experiments. Error bars represent   ±   standard deviation. (H) CL-containing liposomes were incubated with caspase-8 and either 
washed once in binding buffer, or in alkalic (0.1 M Na  2  CO  3  , pH 11.5) or high-salt (1 M NaCl) buffers. After precipitation of liposomes, caspase-8 levels 
were assessed by immunoblotting. The input lane is as in G.     
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  Figure 8.       Caspase-8 C360S colocalizes with tBid on the mitochondria.   (A) Parental or Bcl-xL  –  overexpressing HeLa cells were transfected with either empty 
vector (EGFPN1) or with a plasmid encoding the caspase-8  –  GFP fusion protein. Green cells were analyzed by FACS for viability using PI exclusion. Error 
bars represent   ±   standard deviation. (B) The indicated HeLa cells were either left untransfected or transfected with the caspase-8  –  GFP fusion protein. 24 h 
later, cells were lysed and analyzed for PARP cleavage (using anti-cleaved PARP antibody) as an indicator of cell death. (C) HeLa cells were either left 
untransfected or transfected with the indicated caspase-8  –  GFP protein. The presence of the different caspase-8 processed forms was detected using different 
anti  –  caspase-8 antibodies. (D) Control and tafazzin-knockdown cells were transfected with caspase-8 C360S mutant fused to m-Cherry (C8C360S  –
  m-Cherry), and 24 h later, cells were ﬁ  xed and stained for TOM20 as a mitochondrial marker. Alexa 647  –  conjugated secondary antibody was used for 
a far-red ﬂ  uorescence detection of the mitochondria (artiﬁ  cially presented in green). (E) Control HeLa cells were transfected with C8C360S  –  m-Cherry and 
tBid-GFP in the presence of zVAD-fmk, and 16 h later, cells were ﬁ  xed and analyzed by confocal microscopy. Bars, 10   μ  m.     
the steps required for apoptosis in response to tBid, such as Bak 
oligomerization and mitochondrial outer membrane permeabi-
lization. This prompted investigation of the impaired apoptotic 
process, focusing on the pathway connecting Fas to the mito-
chondria, and revealing that the major block is at the level of 
caspase-8 activation. We propose that CL is required for the 
processing of caspase-8 on mitochondria, and that the interac-
tion with CL is crucial for caspase-8 activation in type II cells. 
  The activation of initiator caspases requires an activating 
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paction of the left ventricular myocardium (  Bleyl et al., 1997  ), 
and a similar defect was observed in mice defi  cient in caspase-8 
(  Varfolomeev et al., 1998  ). Therefore, it is possible that the devel-
opmental abnormalities associated with Barth syndrome are 
due, at least partially, to inactivation of caspase-8. The role of 
mitochondria-associated caspase-8 in several in vivo processes 
should be further investigated. 
  Materials and methods 
  Plasmids and expression vectors 
  To generate the pEGFP/Taz expression vector, human   tafazzin   cDNA was 
ampliﬁ  ed by PCR and inserted, in-frame, into the HindIII and SalI sites of 
pEGFPN1. The   tafazzin   targeted siRNA sequence (GGGAAAGTGAACAT-
GAGTTTT) was used to generate a short hairpin double-stranded DNA (ds-
DNA) oligonucleotide, which was then cloned into pS  UPER/  RetroGFPNeo 
(Oligoengine) to generate the pSUPER/shTaz vector. The nonspeciﬁ  c short 
hairpin dsDNA oligonucleotide was ligated into pSUPERGFPNeo (Oligo-
engine) to generate the pSUPER/shCont vector. To generate an siRNA-resistant 
  tafazzin   cDNA clone (pcDNA3/Taz  mut  ), the human   tafazzin   cDNA was 
cloned into pcDNA3, and the siRNA recognition sequence was mutated at 
the third position of the 182, 183, and 184 codons to conserve the amino 
acid sequence while protecting the mutated transcript from the siRNA effect. 
  Cells culture and transfection 
  The lymphoblastoid cells lines were generated from two unrelated Barth syn-
drome patients (DB105.2 and DB105.3) or two different controls (DB037 
and DB015.2), and were a gift from R. Kelley (Johns Hopkins University 
School of Medicine, Baltimore, MD). DB105.2 and DB105.3 express ta-
fazzin containing a single point mutation at G197E or I209D, respectively, 
which inactivates the protein. Lymphoblasts were immortalized ex vivo by 
Epstein-Barr virus infection. These cells were cultured in RPMI 1640 supple-
mented with 10% FCS, 2 mM   L-  glutamine, penicillin, and streptomycin. The 
cervical carcinoma HeLa cell lines were cultured in DME supplemented with 
10% FCS and   L-  glutamine. Transfection of HeLa cells was performed using 
Lipofectamine 2000 (Invitrogen). Bcl-xL, shTaz, and shCont stable HeLa cell 
lines were generated by transfection with pcDNA3/Bcl-xL, pSUPER/shTaz, 
or pSUPER/shCont, respectively, and selected in G418. The revertant shTaz1R 
cell line was generated by cotransfecting shTaz1 HeLa cells with pLpC vector 
(for the puromycin resistance gene), and pcDNA3/Taz  mut   and stable clones 
were selected in puromycin. 
  For siRNA transfection, unless otherwise stated, HeLa cells were 
transfected with 50 nM of the indicated siRNA, and the efﬁ  ciency of gene 
silencing was validated by Western blotting 48 h after transfection. The se-
quence targeted by siBid and siTaz were GAAGACATCATCCGGAATATT 
and GGGAAAGTGAACATGAGTTTT, respectively. A nontargeting siRNA 
pool (Thermo Fisher Scientiﬁ  c) was used as control. 
  Lipid analysis 
  Lipid analysis was performed as described previously (  Valianpour et al., 
2002  ). Cells were sonicated for 20 s in PBS, and phospholipids were 
  Figure 9.       Caspase-8 oligomerizes on the mito-
chondrial outer membrane.   Control HeLa cells 
(shCont1) were either left untreated or treated 
with anti-Fas antibody for 14 h, and mitochondria 
were isolated in the presence (BMH) or absence 
(DMSO) of a protein cross-linker. Subunit 6 of 
complex I was used as loading control. The dif-
ferent proposed caspase-8 oligomers are in-
dicated on the right. Asterisks indicate higher 
molecular weight multimers of caspase-8.     
triggering complexes include the DISC for caspase-8 and -10 
(  Kischkel et al., 1995  ), the apoptosome for caspase-9 (  Zou et al., 
1999  ), the PIDDosome for caspase-2 (  Tinel and Tschopp, 2004  ), 
and the infl  ammasome for caspase 1 and 5 ( Martinon et al., 2002 ). 
In this work, CL was identifi  ed as a potential new mitochondria-
associated triggering platform required for caspase-8 transloca-
tion, oligomerization, and activation after Fas signaling in type II 
cells. Our data show that once the fi  rst cleavage of procaspase-8 
occurs, the p43/p10 heteromer product inserts into the mitochon-
drial membrane, where it further oligomerizes and may potentially 
undergo cleavage to form a mitochondria-associated p18  –  p10 
  active complex. Though CL is mostly found in the mitochondrial 
inner membrane, several works have demonstrated an enrichment 
of CL in the contact sites between the inner and the outer mito-
chondrial membranes (  Ardail et al., 1990  ;   Hovius et al., 1990  ; 
  Simbeni et al., 1991  ;   Lutter et al., 2001  ;   Kim et al., 2004  ). At the 
contact sites, CL mediates the binding of tBid to the mitochon-
drial outer membrane (  Lutter et al., 2001  ). Therefore, it is likely 
that caspase-8 binding to the mitochondria is regulated in a similar 
way. It remains to be determined whether other proteins, such as 
BAR and FLASH, which were shown to mediate caspase-8 trans-
location to the mitochondria (  Zhang et al., 2000  ;   Milovic-Holm 
et al., 2007  ), play an auxiliary role in these processes. 
  In this paper, the role of CL in apoptosis was studied in cells 
after Fas activation. However, caspase-8 also operates in response 
to other death signals. Caspase-8 prevents metastasis formation 
from primary tumors (  Stupack et al., 2006  ). It will be interesting to 
learn whether mitochondria in general and CL in particular are re-
quired for activating caspase-8 under these conditions, and whether 
CL levels are altered during advanced tumor development. A de-
crease in tafazzin expression levels has been reported in B cell lym-
phoma and breast carcinoma, which suggests that tafazzin loss may 
contribute to tumor progression (  Wilson et al., 2002  ;   Kobayashi 
et al., 2003  ). To date, Barth syndrome has not been associated with 
apoptotic defects or cancers. However, most cells in vivo are type I, 
and the mitochondrial amplifi  cation steps are only required in cells 
in which the DISC has been compromised, as is the case in many 
epithelial cancer cells (  Shell et al., 2007  ). In addition, the early 
mortality age of Barth syndrome patients may explain the absence 
of increased cancer incidents. Importantly, however, Barth syn-
drome is often characterized by a developmental defect of noncom-JCB • VOLUME 183 • NUMBER 4 • 2008  694
University of Pennsylvania, Philadelphia, PA), anti  –  human Bid (Cell Signal-
ing Technology), anti  –  mouse Bid (Santa Cruz Biotechnology, Inc.), anti  –
  caspase-3 (Cell Signaling Technology), anti  –  caspase-8 p43/p18 domain 
(Cell Signaling Technology), anti  –  caspase-8 DED domain (BD), anti  –
    cytochrome   c   (7H8.2C12; BD), anti  –  complex I (NADH dehydrogenase 
subunit 6; Invitrogen), anti  –  complex IV (cytochrome   c   oxidase IV; Invitro-
gen), anti  –  complex II (succinate dehydrogenase subunit B; Invitrogen), anti-
PARP (BD), anti –  cleaved PARP (Cell Signaling Technology), anti-Smac/Diablo 
(BD), and anti-tafazzin (Abcam). 
  Cell fractionation 
  HeLa cells were harvested and washed twice in cold PBS. Cells were then 
washed once in cold mitochondria isolation buffer (MIB; 200 mM manni-
tol, 70 mM sucrose, 1 mM EGTA, 10 mM Hepes, and 0.05% BSA, pH 
7.4). Pellets were then resuspended in 1 ml of MIB and incubated at 4  °  C 
for 5 min. The cells were homogenized in Dounce homogenizer. The nuclei 
were separated and discarded by centrifugation at 750   g   for 5 min, and 
the mitochondria and cytosolic fractions were ﬁ  nally separated by centrifu-
gation at 10,000   g  . The mitochondria-enriched fractions were resuspended 
in a minimal volume of MIB, and the mitochondrial and cytosolic protein 
concentrations were assessed using the BCA Protein Assay kit (Thermo 
Fisher Scientiﬁ  c). 
  In vitro cytochrome   c   and Smac/Diablo release 
  Mitochondria were isolated from HeLa or lymphoblastoid cells, as de-
scribed in   “  Cell fractionation.  ”   Isolated mitochondria were resuspended at 
0.5 mg/ml in a reaction buffer (125 mM KCl, 1 mM KH  2  PO  4  , 2.5 mM 
MgCl  2,   0.2 mM EGTA, 5 mM Hepes, and 0.1% BSA, pH 7.4) in the pres-
ence of 10 mM succinate and 1   μ  M rotenone. After 5 min incubation at RT, 
the recombinant tBid protein (a gift from L. Scorrano, University of Padua, 
Padua, Italy) was added at the indicated concentrations and mitochondria 
were incubated for 15 min at 37  °  C. Mitochondria were then collected by 
centrifugation at 10,000   g   for 5 min. Supernatants and pellets were ana-
lyzed by immunoblotting. 
  Protein oligomerization analyses 
  For the analysis of oligomerization of Bak and/or caspase-8, mitochondria 
were incubated for 30 min at room temperature in the presence of DMSO 
(control) or 10 mM BMH (Thermo Fisher Scientiﬁ   c). Mitochondria were 
then pelleted, and the cross-linking reaction was quenched by addition of 
NuPAGE sample buffer containing DTT. Pellets were then analyzed by SDS-
PAGE in a 4  –  12% acrylamide gradient gel (NuPAGE; Invitrogen), followed 
by immunoblotting. 
  For the analysis of endogenous caspase-8 oligomerization on the 
mitochondria, cells were trypsinized, washed in PBS, resuspended in cross-
linking buffer (210 mM mannitol, 70 mM sucrose, 1 mM EGTA, and 5 mM 
Hepes, pH 7.4), and permeabilized using 0.05% digitonin (EMD). 10 mM 
BMH (or DMSO for control) was added, and the permeabilized cells were 
incubated for 30 min at RT. The cells were then homogenized with a 
Dounce homogenizer, and mitochondrial fractions were prepared as de-
scribed in   “  Cell fractionation.  ”   Mitochondrial pellets were resuspended in 
protein sample buffer containing DTT and analyzed by 4  –  12% gradient 
SDS-PAGE (NuPAGE). 
  Alkaline wash and trypsinization of mitochondrial proteins 
  Isolated mitochondria were incubated for 30 min at 4  °  C in MIB buffer contain-
ing 0.1 M Na  2  CO  3   (pH 11.5). The mitochondrial membranes, containing the 
integrated proteins, were pelleted by ultracentrifugation at 100,000   g   for 30 
min at 4  °  C. The supernatants were also collected. Both fractions were then an-
alyzed by Western blotting. The efﬁ  ciency of the alkaline extraction was con-
trolled using two mitochondrial proteins, NADH-dehydrogenase subunit 6 (an 
integral membrane protein) and succinate dehydrogenase subunit B (loosely 
associated to the matrix side of the mitochondrial inner membrane). 
  The susceptibility of mitochondria-associated caspase-8 to trypsin di-
gestion was checked by isolating mitochondria from HeLa cells transiently 
expressing caspase-8  –  C360S-GFP in the presence of zVAD-fmk (EMD). Iso-
lated mitochondria were resuspended in trypsin digestion buffer and incu-
bated with various concentrations of trypsin (Sigma-Aldrich) for 20 min on 
ice. The proteolysis was stopped by the addition of a 10-fold excess of soy-
bean trypsin inhibitor (Sigma Aldrich). Mitochondria were pelleted at 
100,000   g   for 30 min at 4  °  C and analyzed by immunoblotting. 
  Liposome preparation and analysis 
  The lipid composition of liposomes was based on the composition of 
mitochondrial contact sites as described previously (  Lutter et al., 2000  ). 
Liposomes containing CL consisted of 41 mol% (molar percentage) PC, 
extracted from the equivalent of 1 mg of protein of the homogenates as fol-
lows: after the addition of 3 ml of 1:1 chloroform/methanol (vol/vol), the 
internal standards (0.4 nmol of tetramyristoyl-CL and 0.16 nmol of dimyristoyl-
phosphatidylglycerol; Avanti Polar Lipids) were added. This mixture was 
shaken vigorously and placed on ice for 15 min, after which it was centri-
fuged at 1,000   g   for 10 min. The supernatant was transferred to new tubes, 
and the protein pellet was reextracted with 3 ml of 2:1 chloroform/methanol 
(vol/vol). The combined organic layers were evaporated under nitrogen at 
45  °  C. The residue was dissolved in 150   μ  l chloroform/methanol/water 
(50:45:5 vol/vol/vol) containing 0.01% NH  4  OH, and 10   μ  l of the solution 
was injected into the HPLC mass spectrometry system (Thermo Electron Cor-
poration). The column temperature was maintained at 25  °  C. The lipid extract 
was injected onto a 2.1   ×   250 mm silica column with 5-  μ  m particle diameter 
(Merck). The phospholipids were separated from interfering compounds by 
a linear gradient between solution B (97:3 chloroform/methanol, vol/vol) 
and solution A (85:15 methanol/water, vol/vol). Solution A and B contained 
0.1 ml and 0.01 ml of 25% (vol/vol) aqueous ammonia per liter of eluent, 
respectively. The gradient (0.3 ml/min) was as follows: 0  –  10 min, 20% A 
to 100% A; 10  –  12 min, 100% A; 12  –  12.1 min, 100% A to 0% A; and 
12.1  –  17 min, equilibration with 0% A. All gradient steps were linear, and 
the total analysis time, including the equilibration, was 17 min. A splitter be-
tween the HPLC column and the mass spectrometer was used, and 75   μ  l/min 
eluent was introduced into the mass spectrometer. A TSQ Quantum AM (Thermo 
Fisher Scientiﬁ  c) was used in the negative electrospray ionization mode. 
Nitrogen was used as nebulizing gas. The source collision-induced dissocia-
tion collision energy was set at 10 V, the spray voltage used was 3,600 V, 
and the capillary temperature was 300  °  C. Mass spectra of CL and MLCL 
molecular species were obtained by continuous scanning from m/z 400 to 
m/z 1,000 with a scan time of 2 s. The spectra of CL and MLCL species were 
acquired during their corresponding retention time in the HPLC elution pro-
ﬁ  le. The CL internal standard was set at 100% in each spectrum. 
  Induction and assessment of cell death 
  Cells were treated with the optimal concentrations (0.3   μ  g/ml for lympho-
blastoid cells or 0.5   μ  g/ml for HeLa cells) of an CH11 anti-Fas antibody 
clone (Millipore) or with the indicated amounts of etoposide or cisplatin. 
Cells were stained with PI (Invitrogen) alone or in combination with FITC-
tagged Annexin V (BD). Cell death was quantiﬁ  ed by FACS (BD). 
  Caspase activities were monitored using the caspase-3 and cas-
pase-8 detection kits (EMD) according to the manufacturer  ’  s instructions, 
and analyzed by FACS. Alternatively, isolated mitochondria were incu-
bated for 1 h at room temperature at a 1:1 dilution with caspase-Glo 8 
  reagent (Promega). The relative light unit (RLU) produced by caspase-8 
cleavage of zLETD-aminoluciferin was recorded using GLOMAX software 
on a microplate luminometer (Veritas; Turner Biosystems). 
  For precipitation of active caspase-8, shCont1 and shTaz2 HeLa 
cells were treated with anti-Fas antibody for 16 h. After treatment, cells 
were lysed in a solubilization buffer supplemented with protease inhibitors 
and bVADfmk (EMD). Active caspase-8 was precipitated for 6 h at 4  °  C 
using streptavidin-agarose (EMD) and analyzed by immunoblotting. 
  For immunostaining of cytochrome   c   and Smac/Diablo, HeLa cells 
were seeded on coverslips at 2   ×   10 
5   cells/ml and treated with anti-Fas 
antibody in the presence of 20   μ  M DEVD-fmk. 12 h after treatment, cells 
were ﬁ  xed in 3.7% paraformaldehyde and then permeabilized in PBS/0.2% 
Triton X-100 and blocked in 10% FCS for 1 h. Samples were stained using 
anti  –  cytochrome   c   antibody (BD) or anti-Smac/Diablo antibody (BD), and 
then incubated with cyanine 3 –  conjugated anti –  mouse IgG (Jackson Immuno-
Research Laboratories). The coverslips were ﬁ  nally mounted in medium 
containing DAPI (Vectashield; Vector Laboratories). Samples were analyzed 
under a confocal microscope (SP2; Leica). 
  Immunoﬂ  uorescence microscopy 
  In general, cells were grown in 6-well plates on coverslips. Cells were 
washed with PBS and ﬁ  xed in 4% PFA for 20 min at RT. When appropriate 
cells, were permeabilized in 0.2% Triton X-100 in PBS, blocked with 5% 
BSA, and incubated overnight in anti-TOM20 (Santa Cruz Biotechnology, 
Inc.). Coverslips were washed and incubated in anti  –  rabbit IgG conju-
gated to Alexa 647 (Invitrogen) for 1 h and then mounted in immunoﬂ  uo-
rescence mounting medium (Vectashield; Vector Laboratories). Specimens 
were analyzed at room temperature using a confocal microscope (SP2 
DMIRBE laser scanning confocal with SP2 software) equipped with a 
63  ×  /1.32 NA ph3 oil HCX Plan Apo lens (all from Leica). 
  Immunoblot analysis 
  Antibodies used for immunoblot analyses were: anti  –      -actin (Sigma-
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for the lack of CL. Bovine liver PC, PE, and PI were obtained from Avanti 
Polar Lipids, Inc., and bovine heart CL (    98% pure,   >  80% polyunsatu-
rated fatty acids, primarily linoleic acid) and cholesterol were obtained 
from Sigma-Aldrich. For the preparation of the liposomes, lipids were dis-
solved in chloroform, dried under nitrogen, and resuspended in binding 
buffer containing 100 mM NaCl, 2 mM MgCl  2  , and 10 mM Tris, pH 7.1. 
The lipid mixture was passed 11 times through a 400-nm polycarbonate 
membrane of a Mini-Extruder (Avanti Polar Lipids, Inc.) to form large uni-
lamellar vesicles. After precipitation and wash of liposomes at 100,000   g   
for 15 min at 4  °  C, the presence or absence of CL was conﬁ  rmed by mass 
spectrometry analysis. The indicated proteins were incubated with the lipo-
somes in binding buffer at 37  °  C for 30 min, and liposomes were then cen-
trifuged, washed in binding buffer, 0.1 M Na  2  CO  3  , pH 11.5, or 1 M NaCl, 
and lysed for protein analysis by immunoblotting. 
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content of shCont1, shCont2, shTaz1, and shTaz2. Fig. S5 shows the ex-
pression of and localization of tafazzin-GFP and that transient knockdown 
of tafazzin did not alter CL levels or prevent cell death induced by anti-Fas 
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.org/cgi/content/full/jcb.200803129/DC1. 
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